Federal health regulators have approved an attention deficit disorder drug for a new use: A first-of-its kind treatment for binge-eating disorder.

The Food and Drug Administration first approved Vyvanse as a once-a-day pill for hyperactivity disorder in 2007. On Friday the agency cleared the drug for adults who compulsively overeat.

Regulators approved the new use based on two studies in which adults with a history of had fewer instances per week while taking Vyvanse, compared with those getting a placebo.

Side effects of the drug, made by Shire PLC, can include psychiatric problems like hallucinations and mania as well as heart complications.

Shire PLC is an Irish-headquartered company based on the island of Jersey.